IBAB Ion Beam Applications SA

IBA – ACQUISITION OF OWN SHARES

IBA – ACQUISITION OF OWN SHARES

Immediate Release – September 24th, 2021

Louvain-la-Neuve, Belgium, September 24th, 2021 - In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA”) hereby discloses information in relation to its share buyback program announced on June 29th, 2021.

Under this program, IBA has requested a financial intermediary to repurchase up to 250.000 IBA ordinary shares on its behalf under the terms of a discretionary mandate agreement with validity until December 30th, 2021, effective as from June 30th, 2021, to cover the company’s obligations under a long term incentive plan for certain members of its personnel.

In the framework of this share buyback program, IBA repurchased 11.792 IBA shares on Euronext Brussels in the period from September 17th, 2021 up to and including September 23th, 2021, as follows:

The total number of shares purchased under this program therefore amounts to 208.432. As a result, the current situation with respect to treasury shares (held directly by IBA SA and indirectly through its subsidiary IBA Investments SCRL) is the following:

About IBA

IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA is also a leading player in the fields of industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 1,500 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.

IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

More information can be found at:

Contact person

IBA

Christian Matton,

IBA Chief Legal Officer

Attachment



EN
24/09/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ion Beam Applications SA

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

Ackermans & van Haaren: Expect buoyed contribution from Private Banking. ASR: 1H: strong solvency, buyouts at 12% IRR. Deceuninck: Weak set of results, as expected following the change in CEO. EVS: Very weak 1H25, but guidance unchanged; convincing bolt-on deal in the US. IBA: IBA to install one P1 system at university campus in Heidelberg, Germany. NEPI Rockcastle: Robust performance, small upward revision to guidance

Guy Sips ... (+7)
  • Guy Sips
  • Kristof Samoy
  • Livio Luyten
  • Michiel Declercq
  • Thomas Couvreur
  • Wim Hoste
  • Wim Lewi
 PRESS RELEASE

Heidelberg University Hospital expands its particle therapy program wi...

Heidelberg University Hospital expands its particle therapy program with IBA’s Proteus®ONE solution Louvain-La-Neuve, Belgium, August 20, 2025 – (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer and Heidelberg University Hospital (Universitätsklinikum Heidelberg AöR, UKHD) announce today that they have signed a contract to install a Proteus®ONE1 compact proton therapy solution to be located on the University campus in Heidelberg, Germany. The first payment ...

 PRESS RELEASE

L'hôpital universitaire de Heidelberg élargit son programme de thérapi...

L'hôpital universitaire de Heidelberg élargit son programme de thérapie par particules avec une solution Proteus®ONE Louvain-la-Neuve, Belgique, le 20 août 2025 - IBA (Ion Beam Applications S.A., EURONEXT), le leader mondial des technologies d’accélération de particules et principal fournisseur de solutions de protonthérapie pour le traitement du cancer, et l'hôpital universitaire de Heidelberg (Universitätsklinikum Heidelberg AöR, UKHD) annoncent aujourd'hui la signature d'un contrat pour l'installation d'une solution compacte de protonthérapie Proteus®ONE1  sur le campus universitaire...

 PRESS RELEASE

IBA Notice of Half Year 2025 Results and Conference Call

IBA Notice of Half Year 2025 Results and Conference Call HY25 results webcast to take place on Thursday, 28 August 2025 at 3pm CEST Louvain-la-Neuve, Belgium, 07 August 2025 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, announces today that it will publish its consolidated results for the half year 2025 on Thursday, 28 August 2025 at 7am CEST. Conference Call Information IBA’s management team will host team will host a conference call and webcast conducted in English to present the half year results, followed by a Q&A session. The con...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch